Lee V, Hungerford J L, Bunce C, Ahmed F, Kingston J E, Plowman P N
Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospital London, UK.
Br J Ophthalmol. 2003 Nov;87(11):1374-80. doi: 10.1136/bjo.87.11.1374.
To quantify the rates of eye preservation and patient survival, local tumour relapse and recurrence, and development of new tumours in the remaining eye of children with bilateral retinoblastoma with one eye already enucleated. Also, in the same children, to describe the types of primary and secondary treatment procedures, and to define the anatomical outcome.
This is a retrospective observational case series report. The study participants consisted of 107 patients with bilateral retinoblastoma with one eye enucleated within 1 month of baseline examination and had their remaining eye treated conservatively. The main outcome measure were: primary treatment failures, new tumours, enucleation of the only eye, death, remission, and anatomical outcomes (retinal detachment, vitreous haemorrhage, and cataract).
The median age at diagnosis was 8.4 (range 0.2-44, SD 10.1) months with a median ophthalmic follow up of 44.3 (8.1-114, SD 10.1) months. In 22 of the 107 patients (21%) the treated eye was in Reese Ellsworth groups I or II and in the remaining 85 (79%) in groups III-V at diagnosis. The primary treatment was cryotherapy in 14% (15/107) of eyes, radioactive plaque brachytherapy in 3.7% (4/107), and chemotherapy in 10% (11/107). It was lens sparing radiotherapy in 37% (40/107), whole eye radiotherapy in 29% (31/107), combined radiotherapy and chemotherapy in 2.8% (3/107), chemothermotherapy in 0.9% (1/107), and combined focal therapy in 1.8% (2/107). The primary treatment failed to achieve local tumour control during the follow up period in 37% (40/107) of eyes. In 17 eyes failure was due to inadequate control of the presenting tumour, in 16 to development of a new tumour, and in eight eyes to a combination of both. 35 (88%) of the 40 failures were managed by secondary conservative treatment and the remaining five were treated by enucleation of the only eye. There were eight (7.4%) deaths and the 3 year survival rate was 93% (100/108). Anatomical results included vitreous haemorrhage in four cases, tractional retinal detachment also in four cases, and 24 children required cataract surgery.
Aggressive conservative treatment achieved a good rate of globe salvage without impairing survival.
量化已摘除一眼的双侧视网膜母细胞瘤患儿另一眼的眼球保留率和患者生存率、局部肿瘤复发率以及新肿瘤的发生率。同时,描述同一批患儿的一级和二级治疗程序类型,并明确解剖学结果。
这是一篇回顾性观察病例系列报告。研究参与者包括107例双侧视网膜母细胞瘤患者,这些患者在基线检查后1个月内摘除了一眼,并对其另一眼进行了保守治疗。主要观察指标包括:一级治疗失败、新肿瘤、唯一眼摘除、死亡、缓解以及解剖学结果(视网膜脱离、玻璃体积血和白内障)。
诊断时的中位年龄为8.4(范围0.2 - 44,标准差10.1)个月,眼科中位随访时间为44.3(8.1 - 114,标准差10.1)个月。107例患者中,22例(21%)治疗眼在诊断时处于里斯·埃尔斯沃思分类的I或II组,其余85例(79%)处于III - V组。一级治疗中,14%(15/107)的眼采用冷冻疗法,3.7%(4/107)采用放射性敷贴近距离放疗,10%(11/107)采用化疗。37%(40/107)采用保留晶状体放疗,29%(31/107)采用全眼球放疗,2.8%(3/107)采用放疗与化疗联合治疗,0.9%(1/107)采用化疗热疗,1.8%(2/107)采用联合局部治疗。在随访期间,37%(40/107)的眼一级治疗未能实现局部肿瘤控制。40例治疗失败中,17例是由于对现有肿瘤控制不足,16例是由于出现新肿瘤,8例是两者皆有。40例治疗失败中有35例(88%)通过二级保守治疗处理,其余5例通过摘除唯一眼治疗。有8例(7.4%)死亡,3年生存率为93%(100/108)。解剖学结果包括4例玻璃体积血,4例牵引性视网膜脱离,24例患儿需要进行白内障手术。
积极的保守治疗在不影响生存率的情况下实现了较高的眼球挽救率。